According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular ...
Aug 27, 2012
0
0
(HealthDay)—For patients with stage II pancreatic cancer, attempted surgery with margin-positive resection may offer survival benefit over chemotherapy alone, according to a study published online March 26 in the Journal ...
Apr 22, 2021
0
2
Just six months of exercise can improve memory, language, thinking and judgment problems by almost 50 per cent, says a study presented today at the Canadian Stroke Congress.
Oct 1, 2012
0
0
UVA Health researchers have identified a potential treatment to prevent severe COVID-19 in patients at great risk.
Mar 13, 2023
0
35
Lung cancer patients with diabetes tend to live longer than patients without diabetes, according to a Norwegian study published in the November issue of the Journal of Thoracic Oncology, the official publication of the International ...
Oct 17, 2011
0
0
A new "toolkit" for senior doctors and hospital managers, that will help make changes to their organizational arrangements and improve the quality of hip fracture care across the U.K. has been launched by The Royal Osteoporosis ...
Mar 6, 2023
0
8
Restrictions on eligibility for health care reform programs will result in the potential exclusion of up to 220,000 children from affordable health care coverage in California, according to a new policy brief from the UCLA ...
Jun 30, 2011
0
0
A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair ...
Apr 18, 2023
0
9
A pioneering behavioral diagnostic tool developed by Kingston University and health care technology company Observia to help patients take their medication as prescribed is the first holistic model in the world to accurately ...
Mar 20, 2023
0
8
(Medical Xpress)—A new cancer drug designed to be effective in tumours with faulty BRCA genes has generated impressive responses in an early-stage clinical trial.
Jun 6, 2013
0
0
